港股異動丨利好疊加 歌禮制藥(1672.HK)大漲超13% 8日累計飆升75%
格隆匯1月19日丨歌禮制藥(1672.HK)持續走強,現漲幅擴大至13%,錄得8日連漲75%。現報6.31港元創10個月新高價,總市值近70億港元。近期公司利好消息不斷。18日宣佈與老撾Phokam Pharmaceutical Import-Export Co., Ltd簽署採購協議,向其提供公司研發的產品利托那韋片;輝瑞最新試驗顯示新冠肺炎口服藥Paxlovid對奧密克戎變種病毒有效,利托那韋口服片劑是其已經獲批的新冠口服藥物Paxlovid的組成之一;日前公司皮下注射PD-L1抗體ASC22(恩沃利單抗)美國臨牀試驗申請獲批。機構認為,新冠藥物市場規模可能達到百億級。西南證券認為,新冠疫苗、中和抗體、小分子口服藥是抗疫有效組合。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.